An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) - A clinical pharmacology study

Japanese Journal of Chemotherapy

Volumn 56, Issue 3, 2008, Pages 299-312

  Aikawa, Naoki ^a   Kohno, Shigeru ^b   Kaku, Mitsuo ^c   Watanabe, Akira ^d   Yamaguchi, Keizo ^e   Tanigawara, Yusuke ^a  

^a KEIO UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arbekacin; MRSA; Once a day; PK PD

Indexed keywords

ANTIINFECTIVE AGENT; HABEKACIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ABDOMINAL DISTENSION; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; EOSINOPHIL COUNT; ERADICATION THERAPY; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INCIDENCE; JOINT SWELLING; KIDNEY DYSFUNCTION; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PHARMACODYNAMICS; RESPIRATORY TRACT INFECTION; SAMPLE SIZE; SEPSIS; SHOCK; SIDE EFFECT; SKIN DISEASE; STAPHYLOCOCCUS INFECTION; SUBCUTANEOUS TISSUE DISORDER; TACHYCARDIA; TREATMENT OUTCOME; UREA BLOOD LEVEL; VASCULAR DISEASE;

EID: 44849085984     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Craig W A: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
2. Mattie H, Craig W A, Pechere J C: Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989; 24: 281-93
3. Galloe A M, Graudal N, Christensen H R, Kampmann J P: Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39-43
4. Blaser J, Konig C: Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995: 14: 1029-38
5. Barza M, Ioannidis J P A, Cappelleri J C, Lau J: Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45
6. Munckhof W J, Grayson M L, Turnidge J D: A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-63
7. Hatala R, Dinh T, Cook D J: Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25
8. Freeman C D, Strayer A H: Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996: 16: 1093-102
9. Ferriols-Lisart R, Alos-Alminana M: Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health-Syst Pharm 1996; 53: 1141-50
10. Bailey T C, Little J R, Littenberg B, Reichley R M, Dunagan W C: A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95
11. Ali M Z, Goetz M B: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809
12. Hatala R, Dinh T T, Cook D J: Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810-5
13. Kale-Pradhan P B, Habowski S R, Chase H C, Castronova F C: Once-daily aminoglycosides: a meta-analysis of nonneutropenic and neutropenic adults. J Pharm Technol 1998; 14: 22-9
14. Marra F, Partovi N, Jewesson P: Aminoglycoside administration as a single daily dose - An improvement to current practice or a repeat of previous errors? -. Drugs 1996; 52: 344-70
15. Barclay M L, Kirkpatrick C M J, Begg E J: Once daily aminoglycoside therapy - Is it less toxic than multiple daily doses and how should it be monitored? -. Clin Pharmacokinet 1999; 36: 89-98
16. Japanese source.
17. Mandell G L, Bennett J E, Dolin R: Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Elsevier, Pennsylvania, 2005
18. Japanese source.
19. Japanese source.
20. Japanese source.
21. Japanese source.
22. Japanese source.
23. Japanese source.
24. Japanese source.
25. Tanigawara Y, Sato R, Morita K, Kaku M, Aikawa N, Shimizu K: Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 3754-62
26. Japanese source.
27. Japanese source.
28. Japanese source.
29. Japanese source.
30. Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, et al: Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 2004; 24: 473-8